Comparative Analysis of Adverse Drug Reactions (ADRs) between COVID-19 Vaccines and Established Vaccines: A CDC VAERS Database Analysis
Adverse reaction after COVID-19 vaccination
DOI:
https://doi.org/10.47611/jsrhs.v12i4.5431Keywords:
COVID-19, Vaccines, Adverse Drug Reactions, CDC WONDERAbstract
Background: COVID-19 vaccines have been developed rapidly to combat the pandemic, but vaccine hesitancy remains a challenge due to concerns about adverse drug reactions (ADRs). This study aimed to compare the ADR profiles of COVID-19 vaccines with established vaccines and investigate differences between adults and children.
Methods: A retrospective observational study used the VAERS database to analyze ADR reports from January 2021 to December 2022 in the United States. Top ten common ADRs and seven severe ADRs associated with COVID-19 vaccines were studied using the Evans Criteria.
Results: Among the common ADRs, only dyspnea showed disproportionate reporting in COVID-19 vaccines. Severe ADRs, including myocarditis, pneumonia, and cerebrovascular accidents, were disproportionately reported. Age-stratified analysis revealed myocarditis disproportionately reported in both adults and children.
Conclusions: This study provides a comprehensive comparison of ADRs between COVID-19 vaccines and established vaccines. Although some severe ADRs were disproportionately reported, further evaluation is required to establish any causal relationships with COVID-19 vaccine. Continuous monitoring of ADRs is crucial for vaccine safety.
Downloads
References or Bibliography
Anand, P., & Stahel, V. P. (2021). Review the safety of Covid-19 mRNA vaccines: a review.
Patient Safety in Surgery, 15(1), 20. doi:10.1186/s13037-021-00291-9
Ensuring the safety of vaccines in the United States. (2023, April 27). Retrieved 6 August 2023,
from https://www.cdc.gov/vaccines/hcp/conversations/ensuring-safe-vaccines.html
General help for CDC WONDER. (n.d.). Retrieved 6 August 2023, from
https://wonder.cdc.gov/wonder/help/main.html
VAERS. (2022, September 8). Retrieved 6 August 2023, from
https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html
(N.d.). Retrieved 6 August 2023, from https://wonder.cdc.gov/controller/datarequest/D8
Dror, A. A., Eisenbach, N., Taiber, S., Morozov, N. G., Mizrachi, M., Zigron, A., … Sela, E.
(2020). Vaccine hesitancy: The next challenge in the fight against COVID-19.
doi:10.21203/rs.3.rs-35372/v1
Dubé, E., Laberge, C., Guay, M., Bramadat, P., Roy, R., & Bettinger, J. (2013). Vaccine
hesitancy: an overview. Human Vaccines & Immunotherapeutics, 9(8), 1763–1773.
doi:10.4161/hv.24657
El-Shitany, N. A., Harakeh, S., Badr-Eldin, S. M., Bagher, A. M., Eid, B., Almukadi, H., … El-
Hamamsy, M. (2021). Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine
among Saudi residents: A retrospective cross-sectional study. International Journal of General
Medicine, 14, 1389–1401. doi:10.2147/IJGM.S310497
Evans, S. J., Waller, P. C., & Davis, S. (2001). Use of proportional reporting ratios (PRRs) for
signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and
Drug Safety, 10(6), 483–486. doi:10.1002/pds.677
Griffith, J., Marani, H., & Monkman, H. (2021). COVID-19 vaccine hesitancy in Canada: Content
analysis of tweets using the Theoretical Domains Framework. Journal of Medical Internet
Research, 23(4), e26874. doi:10.2196/26874
Guidry, J. P. D., Laestadius, L. I., Vraga, E. K., Miller, C. A., Perrin, P. B., Burton, C. W., …
Carlyle, K. E. (2021). Willingness to get the COVID-19 vaccine with and without emergency use
authorization. American Journal of Infection Control, 49(2), 137–142.
doi:10.1016/j.ajic.2020.11.018
Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., … Weintraub, E. S.
(2021). Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA: The Journal
of the American Medical Association, 326(14), 1390–1399. doi:10.1001/jama.2021.15072
Kouhpayeh, H., & Ansari, H. (2022). Adverse events following COVID-19 vaccination: A
systematic review and meta-analysis. International Immunopharmacology, 109(108906), 108906.
doi:10.1016/j.intimp.2022.108906
MacDonald, N. E., & SAGE Working Group on Vaccine Hesitancy. (2015). Vaccine hesitancy:
Definition, scope and determinants. Vaccine, 33(34), 4161–4164.
doi:10.1016/j.vaccine.2015.04.036
Comparing the differences between COVID-19 vaccines. (2023, May 23). Retrieved 6 August
, from Mayo Clinic website: https://www.mayoclinic.org/coronavirus-covid-
/vaccine/comparing-vaccines
Mesa, D. O., Hogan, A., Watson, O., Charles, G., Hauck, K., Ghani, A. C., & Winskill, P. (2021).
Quantifying the impact of vaccine hesitancy in prolonging the need for Non-Pharmaceutical
Interventions to control the COVID-19 pandemic. doi:10.21203/rs.3.rs-343127/v1
Orenstein, W. A., & Ahmed, R. (2017). Simply put: Vaccination saves lives. Proceedings of the
National Academy of Sciences of the United States of America, 114(16), 4031–4033.
doi:10.1073/pnas.1704507114
Oster, M. E., Shay, D. K., & Shimabukuro, T. T. (2022). [Review of Myocarditis cases after
mRNA-based COVID-19 vaccination in the US-reply]. JAMA: the journal of the American
Medical Association, 327(20), 2020–2021. doi:10.1001/jama.2022.5134
Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., … Hippisley-Cox,
J. (2021). Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2
infection. Nature Medicine, 27(12), 2144–2153. doi:10.1038/s41591-021-01556-7
Piché-Renaud, P.-P., Morris, S. K., & Top, K. A. (2023). A narrative review of vaccine
pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis
after COVID-19 mRNA vaccination. British Journal of Clinical Pharmacology, 89(3), 967–
doi:10.1111/bcp.15625
Riad, A., Põld, A., Kateeb, E., & Attia, S. (2022). Oral adverse events following COVID-19
vaccination: Analysis of VAERS reports. Frontiers in Public Health, 10, 952781.
doi:10.3389/fpubh.2022.952781
Rodriguez-Nava, G., Egoryan, G., Trelles-Garcia, D. P., Yanez-Bello, M. A., & Murguia-Fuentes,
R. (2021). Disproportionality analysis of anaphylactic reactions after vaccination with messenger
RNA coronavirus disease 2019 vaccines in the United States. Annals of Allergy, Asthma &
Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology,
(1), 139–140. doi:10.1016/j.anai.2021.04.004
Sallam, M. (2021). COVID-19 vaccine hesitancy worldwide: A concise systematic review of
vaccine acceptance rates. Vaccines, 9(2), 160. doi:10.3390/vaccines9020160
Salmon, D. A., Dudley, M. Z., Glanz, J. M., & Omer, S. B. (2015). Vaccine hesitancy: Causes,
consequences, and a call to action. American Journal of Preventive Medicine, 49(6 Suppl 4),
S391-8. doi:10.1016/j.amepre.2015.06.009
Shimabukuro, T. T., Nguyen, M., Martin, D., & DeStefano, F. (2015). Safety monitoring in the
vaccine adverse event reporting system (VAERS). Vaccine, 33(36), 4398–4405.
doi:10.1016/j.vaccine.2015.07.035
Simnani, F. Z., Singh, D., & Kaur, R. (2022). COVID-19 phase 4 vaccine candidates,
effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and
nano-based vaccine platforms: a review. 3 Biotech, 12(1), 15. doi:10.1007/s13205-021-03076-0
Singh, A., Khillan, R., Mishra, Y., & Khurana, S. (2022). The safety profile of COVID-19
vaccinations in the United States. American Journal of Infection Control, 50(1), 15–19.
doi:10.1016/j.ajic.2021.10.015
Singh, R. B., Parmar, U. P. S., Kahale, F., Agarwal, A., & Tsui, E. (2023). Vaccine-associated
uveitis after COVID-19 vaccination: Vaccine adverse event reporting system database analysis.
Ophthalmology, 130(2), 179–186. doi:10.1016/j.ophtha.2022.08.027
Troiano, G., & Nardi, A. (2021). Vaccine hesitancy in the era of COVID-19. Public Health, 194,
–251. doi:10.1016/j.puhe.2021.02.025
Understanding the COVID-19 pandemic in real-time. (n.d.). Retrieved 6 August 2023, from
https://www.unglobalpulse.org/project/understanding-the-covid-19-pandemic-in-real-time/
x2 contingency table. (n.d.). Retrieved 6 August 2023, from http://vassarstats.net/tab2x2.html
Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Shapiro, M. (2018). Understanding
modern-day vaccines: what you need to know. Annals of Medicine, 50(2), 110–120.
doi:10.1080/07853890.2017.1407035
Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. (n.d.). Retrieved 6
August 2023, from https://www.who.int/news-room/questions-and-answers/item/herd-immunity-lockdowns-and-covid-19
Published
How to Cite
Issue
Section
Copyright (c) 2023 Shruti Sreekanth, Shreya Sreekanth; Sreekanth Viswanathan
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
